Cirrhosis, Liver Clinical Trial
Official title:
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury
Verified date | April 2023 |
Source | Postgraduate Institute of Medical Education and Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) & cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Status | Active, not recruiting |
Enrollment | 75 |
Est. completion date | June 15, 2023 |
Est. primary completion date | March 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Cirrhosis of any Etiology - Patient with acute kidney injury meeting HRS-AKI criteria Exclusion Criteria: - Hepatocellular carcinoma - Patients with active variceal bleeding - HIV or severe immunocompromised state - Chronic kidney disease (CKD) on renal replacement therapy (RRT), - Previous transjugular intra hepatic portosystemic shunt (TIPS) - Porto-pulmonary hypertension, - Coronary artery disease - Congenital or valvular heart disease - Prosthetic cardiac valves |
Country | Name | City | State |
---|---|---|---|
India | PGIMER | Chandigarh | Delhi |
Lead Sponsor | Collaborator |
---|---|
Postgraduate Institute of Medical Education and Research |
India,
Adebayo D, Neong SF, Wong F. Refractory Ascites in Liver Cirrhosis. Am J Gastroenterol. 2019 Jan;114(1):40-47. doi: 10.1038/s41395-018-0185-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiac output measurement by echocardiography | Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0 and 48 hours after enrollment.
The cardiac output at 7 days after enrollment will also be documented. he Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = [SV * HR]/ 1000 |
Day 0, Day 2, Day 7. | |
Primary | IVC size and collapsibility changes | IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded. | Day 0. | |
Primary | IVC size and collapsibility changes | IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded. | Day 2 | |
Primary | IVC size and collapsibility changes | IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded. | Day 7. | |
Primary | Number of patients with Complete Response in HRS-AKI | Complete response is defined as a reversal in AKI with a final serum Creatinine (sCr) value of = 0.3 mg/dL of the baseline. | Day 7 | |
Primary | Number of patients with Partial Response in HRS-AKI | Partial response is defined as regression in the stage of AKI with a final sCr > 0.3 mg/dL above the baseline. | Day 7 | |
Primary | Number of patients with Non-Response in HRS-AKI | Non-responder is defined if the sCr did not decrease or increased from the baseline. | Day 7 | |
Secondary | Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level | Day 0 and Day 7 | ||
Secondary | Change in NT Pro brain natriuretic peptide (BNP) level | Day 0 and Day 7 | ||
Secondary | Change in plasma renin activity level | Day 0 and Day 7 | ||
Secondary | Change in Galectin-3 level | Day 0 and Day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
Recruiting |
NCT05604274 -
Longitudinal Monitoring of Stool Characteristics
|
||
Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|